These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 28791061)
1. Visual and Anatomical Outcomes of Spironolactone Therapy in Patients with Chronic Central Serous Chorioretinopathy. Falavarjani KG; Amirsardari A; Habibi A; Eshaghi A; Bakhti S; Aghdam KA J Ophthalmic Vis Res; 2017; 12(3):281-289. PubMed ID: 28791061 [TBL] [Abstract][Full Text] [Related]
2. Investigating the efficacy and safety of oral spironolactone in patients with central serous chorioretinopathy. Yavuz S; Balsak S; Karahan M; Dursun B J Fr Ophtalmol; 2021 Jan; 44(1):13-23. PubMed ID: 33279285 [TBL] [Abstract][Full Text] [Related]
3. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Sun X; Shuai Y; Fang W; Li J; Ge W; Yuan S; Liu Q Br J Ophthalmol; 2018 Aug; 102(8):1060-1065. PubMed ID: 29089356 [TBL] [Abstract][Full Text] [Related]
4. Spironolactone in the treatment of central serous chorioretinopathy - a case series. Herold TR; Prause K; Wolf A; Mayer WJ; Ulbig MW Graefes Arch Clin Exp Ophthalmol; 2014 Dec; 252(12):1985-91. PubMed ID: 25138605 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic Efficacy of Spironolactone for Central Serous Chorioretinopathy. Han JY; Kim YJ; Choi EY; Lee J; Lee JH; Kim M; Byeon SH; Kim SS; Lee CS Yonsei Med J; 2022 Apr; 63(4):365-371. PubMed ID: 35352888 [TBL] [Abstract][Full Text] [Related]
6. The effect of nondamaging subthreshold laser therapy in patients with chronic central serous chorioretinopathy. Lee SH; Lee J; Kim M; Roh YJ Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1433-1442. PubMed ID: 38010518 [TBL] [Abstract][Full Text] [Related]
7. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy. Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785 [TBL] [Abstract][Full Text] [Related]
8. Optical Coherence Tomography Parameters as Predictors of Treatment Response to Eplerenone in Central Serous Chorioretinopathy. Borrelli E; Zuccaro B; Zucchiatti I; Parravano M; Querques L; Costanzo E; Sacconi R; Prascina F; Scarinci F; Bandello F; Querques G J Clin Med; 2019 Aug; 8(9):. PubMed ID: 31443376 [No Abstract] [Full Text] [Related]
9. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Breukink MB; Mohr JK; Ossewaarde-van Norel A; den Hollander AI; Keunen JE; Hoyng CB; Boon CJ Acta Ophthalmol; 2016 Mar; 94(2):187-97. PubMed ID: 26670630 [TBL] [Abstract][Full Text] [Related]
10. Oral Spironolactone versus Conservative Treatment for Non-Resolving Central Serous Chorioretinopathy in Real-Life Practice. Sinawat S; Thongmee W; Sanguansak T; Laovirojjanakul W; Sinawat S; Yospaiboon Y Clin Ophthalmol; 2020; 14():1725-1734. PubMed ID: 32612347 [TBL] [Abstract][Full Text] [Related]
11. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY. Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871 [TBL] [Abstract][Full Text] [Related]
12. The Effect of Selective Retina Therapy for Bevacizumab-Resistant Chronic Central Serous Chorioretinopathy. Jeon SH; Kim M; Lee J; Roh YJ Ophthalmologica; 2022; 245(1):91-100. PubMed ID: 34649253 [TBL] [Abstract][Full Text] [Related]
13. Effect of a topical nonsteroidal anti-inflammatory agent (0.1 % pranoprofen) on acute central serous chorioretinopathy. An SH; Kwon YH Graefes Arch Clin Exp Ophthalmol; 2016 Aug; 254(8):1489-1496. PubMed ID: 26553195 [TBL] [Abstract][Full Text] [Related]
15. Role of Avastin in management of central serous chorioretinopathy. Mehany SA; Shawkat AM; Sayed MF; Mourad KM Saudi J Ophthalmol; 2010 Jul; 24(3):69-75. PubMed ID: 23960879 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy. van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468 [TBL] [Abstract][Full Text] [Related]
17. Selective retina therapy with automatic real-time feedback-controlled dosimetry for chronic central serous chorioretinopathy in Korean patients. Park YG; Kang S; Kim M; Yoo N; Roh YJ Graefes Arch Clin Exp Ophthalmol; 2017 Jul; 255(7):1375-1383. PubMed ID: 28421342 [TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F Retina; 2013; 33(10):2096-102. PubMed ID: 23719402 [TBL] [Abstract][Full Text] [Related]
19. Subthreshold laser compared to oral spironolactone for the treatment of chronic central serous chorioretinopathy: a retrospective study. Mercuri S; D'Alterio FM; Gallo B; Raslan W; Gupta A; Khairat N; Corazza P; Younis S Int Ophthalmol; 2024 Mar; 44(1):131. PubMed ID: 38478131 [TBL] [Abstract][Full Text] [Related]
20. Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy. Zola M; Daruich A; Matet A; Mantel I; Behar-Cohen F Br J Ophthalmol; 2019 Aug; 103(8):1184-1189. PubMed ID: 30355720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]